Vancomycin (hydrochloride)

• Description:

  Vancomycin hydrochloride is an antibiotic for the treatment of bacterial infections. It acts by inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin also alters the permeability of the cell membrane and selectively inhibits ribonucleic acid synthesis.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Antibiotic; Autophagy; Bacterial

• Type:

  Natural Products

• Related Pathways:

  Anti-infection; Autophagy

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Vancomycin-hydrochloride.html

• Purity:

  99.43

• Solubility:

  DMSO : 24 mg/mL (ultrasonic; warming) |H2O : 33.33 mg/mL (ultrasonic)

• Smiles:

  ClC1=CC([C@H]([C@@H](NC([C@H](NC)CC(C)C)=O)C(N[C@@H](CC(N)=O)C(N[C@@]2([H])C(N[C@]3([H])C4=CC(C5=C(C=C(O)C=C5O)[C@](C(O)=O)([H])NC([C@](NC3=O)([H])[C@H](O)C6=CC=C7C(Cl)=C6)=O)=C(O)C=C4)=O)=O)=O)O)=CC=C1OC8=C(C(O7)=CC2=C8)O[C@H]9[C@@H]([C@H]([C@H](O)[C@@H](CO)O9)O)O[C@@]%10([H])C[C@](N)([C@H](O)[C@H](C)O%10)C.Cl

• Molecular Formula:

  C66H76Cl3N9O24

• Molecular Weight:

  1485.71

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Rybak MJ, et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9.|[2]Watanakunakorn C, et al. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother. 1984 Dec;14 Suppl D:7-18.|[3]Warren CA, et al. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother. 2013 Feb;57 (2) :689-96.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Natural Products

• Clinical Information:

  Launched

• Isoform:

  Glycopeptide

• Citation 01:

  Cancer Cell. 2025 Sep 25:S1535-6108 (25) 00394-0.|Cell Rep. 2025 Feb 28;44 (3) :115356.|Chem Eng J. 2024 Apr 15, 486 150125.|Front Aging Neurosci. 2022 Jul 28;14:858130.|Front Pharmacol. 2025 Dec 1:16:1657343.|NPJ Biofilms Microbiomes. 2024 Oct 28;10 (1) :111.|PLoS One. 2025 Jul 10;20 (7) :e0328167.|PLoS Pathog. 2025 Jun 9;21 (6) :e1013179.|Pol J Microbiol. 2023 Jun 14;72 (2) :199-208.|Redox Biol. 2023 Nov:67:102929.|Small. 2022 Mar;18 (10) :e2107137.|ACS Infect Dis. 2021 Aug 13;7 (8) :2565-2582.|ACS Infect Dis. 2023 Dec 8;9 (12) :2523-2537.|ACS Infect Dis. 2024 Apr 12;10 (4) :1327-1338.|ACS Infect Dis. 2024 Aug 9;10 (8) :2961-2977.|ACS Infect Dis. 2025 Jun 13;11 (6) :1473-1485.|ACS Omega. 2022 Mar 3;7 (10) :9004-9014.|ACS Omega. 2023 Feb 3;8 (6) :5415-5425.|ACS Omega. 2023 Mar 6;8 (10) :9652-9661.|Adv Funct Mater. 2024 Jun 19.|Adv Sci (Weinh) . 2025 Apr 28:e2409837.|Adv Sci (Weinh) . 2025 Oct 13:e09383.|Am J Chin Med. 2024 Aug 21:1-28.|AMB Express. 2024 Dec 24;14 (1) :141.|Appl Microbiol Biotechnol. 2022 Apr;106 (7) :2689-2702.|Aquaculture. 2021, 736248.|ArXiv. 2025 Nov 7.|Basic Clin Androl. 2025 Mar 7;35 (1) :9.|Biochem Biophys Res Commun. 2025 Jun 7:776:152161.|Biochem Pharmacol. 2024 Dec;230 (Pt 2) :116593.|Biomacromolecules. 2025 Jun 9;26 (6) :3852-3867.|bioRxiv. 2024 May 10.|bioRxiv. 2025 February 13.|Cancer Immunol Res. 2022 Dec 2;10 (12) :1542-1558.|Cell Death Dis. 2021 Jun 7;12 (6) :582.|Cell Metab. 2023 Nov 7;35 (11) :1961-1975.e6.|Cell Metab. 2025 Jan 7;37 (1) :87-103.e10.|Cell Rep Med. 2025 Oct 21;6 (10) :102410.|Chemosphere. 2019 Jun:225:378-387.|Curr Microbiol. 2023 May 31;80 (7) :230.|Curr Res Food Sci. 2025 May 16:10:101084.|Emerg Microbes Infect. 2022 Dec;11 (1) :815-828.|Emerg Microbes Infect. 2024 Dec;13 (1) :2321981.|Environ Health Perspect. 2022 Jun;130 (6) :67009.|Food Funct. 2025 Jul 14;16 (14) :5885-5899.|Front Microbiol. 2020 Jul 31:11:1720.|Future Microbiol. 2025 Oct 13:1-10.|Genome Biol. 2023 Apr 30;24 (1) :98.|Gut Microbes. 2023 Dec;15 (2) :2249143.|Heliyon. 2024 Jan 6;10 (1) :e24239.|Infect Drug Resist. 2021 Dec 16;14:5449-5456.|Int Immunopharmacol. 2025 May 21:159:114888.|Int J Biol Macromol. 2024 Sep 19:135835.|Int J Biol Macromol. 2025 Mar 19:142276.|Int J Med Microbiol. 2020 Jan;69 (1) :120-131.|Int J Med Sci. 2022 Apr 11;19 (4) :740-752.|iScience. 2022 Jan 5;25 (2) :103731.|iScience. 2023 Mar 11;26 (4) :106378.|iScience. 2023 Oct 7;26 (11) :108158.|iScience. 2025 May 13;28 (7) :112658.|iScience. 2025 May 27;28 (6) :112763.|J Agric Food Chem. 2024 Apr 10.|J Appl Microbiol. 2024 Jan 2;135 (1) :lxae001.|J Cell Physiol. 2022 Mar;237 (3) :1845-1856.|J Neuroinflammation. 2025 Nov 4;22 (1) :259.|J Pharm Anal. 2023 Oct;13 (10) :1153-1167.|Life Metab. 2025 Oct 8.|Life Sci. 2020 Nov 15;261:118473.|Microb Biotechnol. 2021 Nov;14 (6) :2538-2551.|Microbiol Spectr. 2022 Apr 27;10 (2) :e0054121.|Microbiol Spectr. 2025 Oct 15:e0122125.|Microbiol Spectr. 2025 Oct 23:e0157625.|Microbiologyopen. 2025 Oct;14 (5) :e70062.|Mol Immunol. 2022 Sep:149:94-106.|Mol Pharm. 2022 Nov 7;19 (11) :4320-4332.|Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398 (4) :3681-3695.|Neural Regen Res. 2024 Sep 1;19 (9) :2081-2088.|Pharmacol Res. 2024 May 21:205:107229.|Phytomedicine. 2024 Nov 28:136:156297.|Res Sq. 2024 Oct 02.|Research Square Preprint. 2020 Jun.|Research Square Preprint. 2024 Nov 13.|Transl Res. 2023 Mar:253:16-30.|Virulence. 2024 Dec;15 (1) :2367659.|Virulence. 2024 Dec;15 (1) :2415952.

• CAS Number:

  1404-93-9